Aim-listed Alliance Pharma has boosted its sales following its takeover of rival Sinclair's healthcare products .
The pharmaceutical giant's pre-tax profits are up a whopping 103 per cent to £22.2m in the year to December while revenues rose 102 per cent to £97.5m.
Why it's interesting
Alliance Pharma's takeover of Sinclair's products helped boost is profits and expand its geographic reach to over 100 countries.
Other highlights included integrating 27 products acquired from Sinclair, effectively doubling the size of the group.
Among its star products were scar gel Kelo-cote and eye supplement MacuShield. Kelo-cote became the pharma giant's first £10m brand last year.
What Alliance Pharma said
Andrew Smith, Alliance's chairman, said:
"2016 has been transformational for Alliance following the acquisition of the Sinclair healthcare products business. Sales and profits have broadly doubled and our geographic reach extends to more than 100 countries. Having successfully integrated the acquisition, we are now focused on our three international growth opportunities - Kelo-cote, MacuShield and Diclectin.
"The current year has started well and we look forward to building on our foundations: an attractive, balanced portfolio, an expanded geographic footprint and a strong team."